Investigational Lenacapavir for HIV Prevention: Remarkable New Results Unveiled
Gilead Sciences’ pivotal Phase 3 PURPOSE 1 trial has revealed compelling efficacy and safety results for lenacapavir, a novel...
Gilead Sciences’ pivotal Phase 3 PURPOSE 1 trial has revealed compelling efficacy and safety results for lenacapavir, a novel...
The AFFINE study evaluating giroctocogene fitelparvovec, a gene therapy for moderate to severe hemophilia A, has achieved significant results....
A groundbreaking alliance between Worldwide Clinical Trials (Worldwide), Centrum Badan Klinicznych PI-House, and the Polish Psychedelic Society (PTP) aims...
BeiGene, a global oncology company, has established its flagship U.S. facility in Hopewell, New Jersey, aiming to bolster its...
ViiV Healthcare’s PASO DOBLE study found that the 2-drug regimen Dovato (DTG/3TC) is as effective as the 3-drug regimen...
Azitra, Inc., a biopharmaceutical company specializing in dermatology, has secured a U.S. patent (No. 12,036,248) for its potential treatment...
Vividion Therapeutics expands its global reach by establishing a new research and development (R&D) center and corporate headquarters in...
A five-year Master Services Agreement (MSA) has been signed between ViroCell Biologics and a prominent U.S. NCI-designated cancer center....
JCR Pharmaceuticals unveiled significant advancements in gene therapy research at the International Forum of Lysosomal Disorders. The company’s proprietary...
Hanger Ventures, a subsidiary of Hanger, Inc., has invested in Bionic Power, a Canadian company developing active lower-body orthotic...